Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$0.95 -15.7%	$1.52	$0.87 ▼ $3.78	$208.38M	0.6	3.35 million shs	13.04 million shs
LFCR Lifecore Biomedical	$6.67 -4.0%	$6.46	$3.68 ▼ $7.99	$246.96M	0.65	234,876 shs	136,815 shs
RNAC Cartesian Therapeutics	$9.98 -2.2%	$12.78	$8.85 ▼ $41.87	$258.85M	0.51	115,863 shs	77,465 shs
ZIVO ZIVO Bioscience	$18.00 +6.1%	$16.65	$3.13 ▼ $22.15	$68.63M	0.03	1,004 shs	5,085 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-3.42%	-11.72%	-22.07%	-20.98%	-61.03%
LFCR Lifecore Biomedical	-0.43%	-0.17%	+19.42%	+21.50%	+13.75%
RNAC Cartesian Therapeutics	-2.30%	-3.50%	-4.40%	-46.09%	-52.45%
ZIVO ZIVO Bioscience	+6.07%	+12.50%	+20.00%	-8.86%	+129.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.6619 of 5 stars	4.5	3.0	0.0	0.0	2.3	3.3	0.6
LFCR Lifecore Biomedical	1.1794 of 5 stars	2.2	0.0	0.0	0.0	1.8	4.2	0.6
RNAC Cartesian Therapeutics	1.6247 of 5 stars	3.4	0.0	0.0	0.0	2.2	3.3	0.0
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.89	832.92% Upside
LFCR Lifecore Biomedical	2.33	Hold	$8.00	19.94% Upside
RNAC Cartesian Therapeutics	2.75	Moderate Buy	$42.50	325.85% Upside
ZIVO ZIVO Bioscience	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZIVO, LFCR, RNAC, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/8/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
4/9/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00
4/9/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/19/2025	ALLO Allogene Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.00
3/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	9,471.91	N/A	N/A	$3.04 per share	0.31
LFCR Lifecore Biomedical	$130.31M	1.90	N/A	N/A	$0.37 per share	18.03
RNAC Cartesian Therapeutics	$34.17M	7.57	N/A	N/A	($82.38) per share	-0.12
ZIVO ZIVO Bioscience	$15.85K	4,330.22	N/A	N/A	($0.81) per share	-22.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.33	N/A	N/A	N/A	N/A	-52.13%	-41.29%	N/A
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-12.52%	-315.23%	-12.74%	N/A
RNAC Cartesian Therapeutics	-$219.71M	-$52.83	N/A	N/A	N/A	-510.72%	N/A	-6.03%	N/A
ZIVO ZIVO Bioscience	-$7.78M	-$4.28	N/A	∞	N/A	N/A	N/A	-2,240.92%	N/A

Latest ZIVO, LFCR, RNAC, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million
4/3/2025	Q3 2025	LFCR Lifecore Biomedical	-$0.14	-$0.19	-$0.05	-$0.47	$33.23 million	$35.15 million
3/13/2025	Q4 2024	ALLO Allogene Therapeutics	-$0.34	-$0.28	+$0.06	-$0.28	$0.01 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
LFCR Lifecore Biomedical	9.21	2.32	1.21
RNAC Cartesian Therapeutics	N/A	10.70	10.70
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
LFCR Lifecore Biomedical	83.36%
RNAC Cartesian Therapeutics	86.95%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
LFCR Lifecore Biomedical	32.20%
RNAC Cartesian Therapeutics	57.90%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.71 million	158.72 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	26.58 million	Optionable
RNAC Cartesian Therapeutics	64	25.94 million	10.70 million	Optionable
ZIVO ZIVO Bioscience	10	3.81 million	2.91 million	Not Optionable

ZIVO, LFCR, RNAC, and ALLO Headlines

Recent News About These Companies

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Crosses Above 50-Day Moving Average - Should You Sell?

April 30, 2025 | marketbeat.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.com

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.com

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 2, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.com

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

Zivo Bioscience to effect reverse stock split to regain compliance with Nasdaq rules

October 26, 2023 | msn.com

Adam Zivo: Nazi veteran’s memoir lays bare the pitfalls of nationalism

October 5, 2023 | nationalpost.com

ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference

October 3, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO, LFCR, RNAC, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$0.95 -0.18 (-15.68%)

As of 04:00 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Lifecore Biomedical NASDAQ:LFCR

$6.67 -0.28 (-4.03%)

As of 04:00 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Cartesian Therapeutics NASDAQ:RNAC

$9.98 -0.22 (-2.16%)

As of 04:00 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

ZIVO Bioscience NASDAQ:ZIVO

$18.00 +1.03 (+6.07%)

As of 05/13/2025 03:59 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time